CardioNova Of Russia Files For Clinical Trials Of Atherosclerosis Drug
This article was originally published in PharmAsia News
Executive Summary
Russia's CardioNova said pre-clinical trials of its AHRO-001 drug for treating dyslipidemia and preventing atherosclerosis produced excellent results leading to a filing for approval to begin human trials.
Russia's CardioNova said pre-clinical trials of its AHRO-001 drug for treating dyslipidemia and preventing atherosclerosis produced excellent results leading to a filing for approval to begin human trials. The drug was developed in partnership with U.S. drug maker AtheroNova. The animal studies showed the drug to be equal to atorvastatin in normalizing cholesterol levels in the blood. (Click here for more)
"A Design Company Of RVC Tested Its Drug Against Atherosclerosis" - Venture News (Russia) (11/13/2012)